Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It delivers a steady release of hormone to provide up to three years of highly effective contraception and is also approved in some regions for the treatment of heavy menstrual bleeding.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality and regulatory compliance.

Levosert, a progestin‑based intrauterine system, is used in reproductive health for contraception and menstrual management.

Contraception: provides up to three years of reversible birth control for women of reproductive age. Heavy menstrual bleeding: reduces menstrual blood loss and improves bleeding patterns where approved. Hormonal contraception: offers a progestin‑only, non‑oral option for women seeking long‑acting contraception.

Levosert may be associated with a range of adverse reactions, most of which are related to local uterine effects or systemic hormone exposure.

Common Side Effects: - Irregular bleeding: spotting or changes in menstrual pattern. - Pelvic pain: cramping during or after insertion. - Headache: mild to moderate intensity. - Breast tenderness: discomfort or swelling.

Serious or Rare Side Effects: - Uterine perforation: rare injury during insertion. - Ectopic pregnancy: possible if contraception fails. - Infection: pelvic inflammatory disease. - Expulsion: device may be expelled spontaneously.

Before using Levosert, several precautions should be considered to ensure safety and effectiveness.

Pregnancy testing: confirm non‑pregnant status before insertion. Uterine abnormalities: assess for fibroids, septa, or malformations. Infection risk: treat active pelvic infection before procedure. Bleeding disorders: evaluate clotting status and advise on potential increased bleeding. Device monitoring: schedule follow‑up visits to check IUS position. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert can interact with other medications that affect hormone metabolism or the uterine environment.

Major Interactions (Avoid): - Enzyme inducers: drugs such as rifampicin or carbamazepine may reduce levonorgestrel levels. - Antifungal azoles: ketoconazole can increase hormone concentrations. - Antiretrovirals: efavirenz may lower contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antibiotics: broad‑spectrum agents (e.g., ampicillin) have limited effect but may require monitoring. - Herbal supplements: St. John’s wort may modestly decrease hormone levels. - Anticonvulsants: phenytoin may modestly reduce efficacy.